Haematologic malignancies
iOnctura SA supports clinical research in myelofibrosis, with attention to patients whose disease remains unresponsive to JAK inhibitors. The portfolio reflects interest in myeloid neoplasms, bone marrow fibrosis, and immune-mediated mechanisms that influence blood cancer progression.
- Myelofibrosis
- JAK inhibitor resistance
- Myeloid malignancies
Research in this area is centred on therapeutic options for advanced blood disorders and on approaches that address persistent disease activity in the haematology setting.
Solid tumours and metastatic cancer
The sponsor funds studies across advanced solid tumours and metastatic cancers, including patients with difficult-to-treat disease. This includes work in non-small cell lung cancer and broader advanced oncology populations where treatment resistance and tumour spread are key concerns.
- Advanced solid tumours
- Metastatic cancer
- Non-small cell lung cancer
Clinical activity in this field also includes combinations with immunotherapy and other oncology agents in settings where standard options are limited.
Ocular and uveal melanoma
iOnctura SA is involved in research for advanced metastatic ocular melanoma and uveal melanoma, rare cancers with strong unmet need in systemic therapy. The focus includes disease control in metastatic melanoma arising from the eye and related uveal tract malignancies.
- Uveal melanoma
- Metastatic ocular melanoma
- Rare melanoma subtypes
This area highlights interest in specialised oncology care for tumours with distinct biological and clinical behaviour.
Combination oncology strategies
The sponsor’s research landscape includes combination-based treatment approaches in oncology, spanning checkpoint inhibition, cytotoxic chemotherapy, and targeted immune modulation. These studies extend across pancreatic cancer, lung cancer, and other metastatic solid tumours.
- Immuno-oncology combinations
- Pancreatic cancer
- Advanced non-squamous NSCLC
Work in this domain reflects therapeutic interest in refractory cancers where multi-agent regimens are used to address immune escape and tumour burden.
Immune regulation in cancer
Across its portfolio, iOnctura SA shows interest in T-cell regulation, regulatory T cells, and broader tumour microenvironment biology. These themes appear in studies exploring immune balance in metastatic malignancies and in cancers with pronounced immune suppression.
- Regulatory T cells
- T-cell mediated immunity
- Tumour microenvironment
The research emphasis is aligned with therapeutic development in cancers where immune modulation is central to clinical management.
